Nobivac® Puppy DP

Combined Freeze-Dried Canine Distemper and Parvovirus Vaccine

Active immunisation of young puppies against canine distemper virus, and canine parvovirus infection.

Thepuppy vaccination programme can becompleted from 10weeks of age and followingcompletion, the components of Nobivac Puppy DP have been shown to protect against canine distemper virus and canine parvovirus for at leastthree years, whilst onset of immunity is one week following administration. Puppy DP can be used at 6weeks of age followed by Nobivac DHP/DHPPi at 10 weeks of age.

Reconstitute each single dose (vial) of the vaccine with one vial(1mL) of Nobivac Diluent or Nobivac Lepto I and administer by subcutaneous injection. Afterreconstitution, the vaccine should be used within 30 minutes.

Primary vaccination
A first dosemay be given topuppies from 6 weeks of age, but because maternally derived antibodies can interfere with response to vaccination, a final dose should be given 4 weeks later i.e. at 10 weeks of age or older. If the first dose is given at 10 weeks of age or older, only one dose is required.

Booster vaccination
Dogs should berevaccinated every 3 years.


  • Only healthy dogs should be vaccinated.
  • Sterileequipment should be used for administration but avoid contamination of vaccine with traces of disinfectant or spirit.


Following subcutaneous administration, a diffuse swelling up to 5mm in diameter may be observed at the site of injection. Occasionally this swelling may be hard and painful and last up to 3 dayspost injection.

In rare cases, a transient rise in body temperature may occur.
Hypersensitivity reactions are rare, but as with all vaccines, may occasionally be encountered. In this event, administration of an antihistamine, corticosteroid or adrenaline by the most immediate route may be indicated.

Store in arefrigerator between 2°C and 8°C. Oncereconstituted use within 30 minutes.
Nobivac Diluent may be stored at room temperature.

The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has proven to be of benefit against virulent challenge in the presence of maternal antibody levels to CDV, CAV2 and CPV that are likely to be encountered under field conditions.
Experience has shown that the maternal parvovirus antibody status of pups within a litter varies greatly and reliance should not be placed on serological examination of the bitch alone.
Agood immune response is reliant on the reaction of a fully competent immune system to an immunogenic agent.The immunogenicity of thevaccine antigen will be reduced by poor storage or inappropriate administration.
Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.